By jeremyc | November 8, 2012
A new study found that the discovery of distinct genetic “signatures” helps in identifying the fastest growing tumors in the prostate cancer patients. The study was conducted by a group of researchers headed by William Oh, M.D. from the Division of Hematology and Medical Oncology of The Tisch Cancer Institute at The Mount Sinai Medical Center in New York City. The results of the study were published in the October issue of The Lancet Oncology.
The aim of the study was to understand the importance of identifying the distinct genetic “signatures” to detect tumors. The researchers conducted the study on 202 men. All the participants of the study were suffering from treatment-resistant prostate cancer. The researchers took the samples of blood and examined them.
The researchers identified six different types of genes that were found only in the body of the patients who were suffering from treatment-resistant prostate cancer.
It was also found that a group of genes in a cell called a signature are the characteristics of some conditions in patients with treatment-resistant prostate cancer.
The researchers found that the men who had six-gene signature were at a higher risk of mortality. Their survival rate was lower, and they were expected to live for 7.8 months.
The researchers also found that the men who didn’t have the six-gene signature were likely to live up to 35 months.
“There is an urgent need for predictive models that help assess how aggressive the disease is in prostate cancer patients, as survival can vary greatly. Our six-gene model, delivered in a simple blood test, will allow clinicians to better determine the course of action for their patients, determine clinical trial eligibility, and lead to more targeted studies in late-stage disease,” said the researchers.
Comments are closed.